Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1993 2
1994 3
1995 1
1996 5
1997 12
1998 42
1999 61
2000 71
2001 102
2002 94
2003 100
2004 102
2005 87
2006 79
2007 51
2008 68
2009 66
2010 74
2011 69
2012 68
2013 59
2014 51
2015 62
2016 67
2017 54
2018 61
2019 62
2020 81
2021 91
2022 80
2023 94
2024 42

Text availability

Article attribute

Article type

Publication date

Search Results

1,795 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean aggrastat (1,826 results)?
Tirofiban for Stroke without Large or Medium-Sized Vessel Occlusion.
Zi W, Song J, Kong W, Huang J, Guo C, He W, Yu Y, Zhang B, Geng W, Tan X, Tian Y, Liu Z, Cao M, Cheng D, Li B, Huang W, Liu J, Wang P, Yu Z, Liang H, Yang S, Tang M, Liu W, Huang X, Liu S, Tang Y, Wu Y, Yao L, Shi Z, He P, Zhao H, Chen Z, Luo J, Wan Y, Shi Q, Wang M, Yang D, Chen X, Huang F, Mu J, Li H, Li Z, Zheng J, Xie S, Cai T, Peng Y, Xie W, Qiu Z, Liu C, Yue C, Li L, Tian Y, Yang D, Miao J, Yang J, Hu J, Nogueira RG, Wang D, Saver JL, Li F, Yang Q; RESCUE BT2 Investigators. Zi W, et al. N Engl J Med. 2023 Jun 1;388(22):2025-2036. doi: 10.1056/NEJMoa2214299. N Engl J Med. 2023. PMID: 37256974 Clinical Trial.
BACKGROUND: The effects of the glycoprotein IIb/IIIa receptor inhibitor tirofiban in patients with acute ischemic stroke but who have no evidence of complete occlusion of large or medium-sized vessels have not been extensively studied. ...The incidence of symptomatic intra …
BACKGROUND: The effects of the glycoprotein IIb/IIIa receptor inhibitor tirofiban in patients with acute ischemic stroke but who have …
Effect of Intravenous Tirofiban vs Placebo Before Endovascular Thrombectomy on Functional Outcomes in Large Vessel Occlusion Stroke: The RESCUE BT Randomized Clinical Trial.
RESCUE BT Trial Investigators; Qiu Z, Li F, Sang H, Luo W, Liu S, Liu W, Guo Z, Li H, Sun D, Huang W, Zhang M, Zhang M, Dai W, Zhou P, Deng W, Zhou Z, Huang X, Lei B, Li J, Yuan Z, Song B, Miao J, Liu S, Jin Z, Zeng G, Zeng H, Yuan J, Wen C, Yu Y, Yuan G, Wu J, Long C, Luo J, Tian Z, Zheng C, Hu Z, Wang S, Wang T, Qi L, Li R, Wan Y, Ke Y, Wu Y, Zhu X, Kong W, Huang J, Peng D, Chang M, Ge H, Shi Z, Yan Z, Du J, Jin Y, Ju D, Huang C, Hong Y, Liu T, Zhao W, Wang J, Zheng B, Wang L, Liu S, Luo X, Luo S, Xu X, Hu J, Pu J, Chen S, Sun Y, Jiang S, Wei L, Fu X, Bai Y, Yang S, Hu W, Zhang G, Pan C, Zhang S, Wang Y, Cao W, Yang S, Zhang J, Guo F, Wen H, Zhang J, Song J, Yue C, Li L, Wu D, Tian Y, Yang J, Lu M, Saver JL, Nogueira RG, Zi W, Yang Q. RESCUE BT Trial Investigators, et al. JAMA. 2022 Aug 9;328(6):543-553. doi: 10.1001/jama.2022.12584. JAMA. 2022. PMID: 35943471 Free PMC article. Clinical Trial.
The median (IQR) 90-day modified Rankin Scale score in the tirofiban group vs placebo group was 3 (1-4) vs 3 (1-4). The adjusted common odds ratio for a lower level of disability with tirofiban vs placebo was 1.08 (95% CI, 0.86-1.36). ...The findings do not support …
The median (IQR) 90-day modified Rankin Scale score in the tirofiban group vs placebo group was 3 (1-4) vs 3 (1-4). The adjusted comm …
Tirofiban-induced thrombocytopenia.
Wang J, Zou D. Wang J, et al. Ann Med. 2023 Dec;55(1):2233425. doi: 10.1080/07853890.2023.2233425. Ann Med. 2023. PMID: 37439782 Free PMC article. Review.
Tirofiban is a small non-peptide ligand-mimetic Glycoprotein (GP) IIb/IIIa inhibitor which can reversibly bind to the arginine-glycine-aspartic acid (RGD) recognition site of GP IIb/IIIa to prevent platelet aggregation. ...The present review provides an overview of the pat …
Tirofiban is a small non-peptide ligand-mimetic Glycoprotein (GP) IIb/IIIa inhibitor which can reversibly bind to the arginine-glycin …
Association of Tirofiban With Functional Outcomes After Thrombectomy in Acute Ischemic Stroke Due to Intracranial Atherosclerotic Disease.
Sang H, Xie D, Tian Y, Nguyen TN, Saver JL, Nogueira RG, Wu J, Long C, Tian Z, Hu Z, Wang T, Li R, Ke Y, Zhu X, Peng D, Chang M, Li L, Ruan J, Wu D, Zi W, Yang Q, Li F, Qiu Z. Sang H, et al. Neurology. 2023 May 9;100(19):e1996-e2006. doi: 10.1212/WNL.0000000000207194. Epub 2023 Mar 20. Neurology. 2023. PMID: 36941074 Clinical Trial.
Tirofiban was associated with fewer thrombectomy passes (median [IQR] 1 [1-2] vs 1 [1-2], p = 0.004), which was an independent predictor of functional independence. Mediation analysis showed tirofiban-reduced thrombectomy passes explained 20.0% (95% CI 4.1%-76.0%) o …
Tirofiban was associated with fewer thrombectomy passes (median [IQR] 1 [1-2] vs 1 [1-2], p = 0.004), which was an independent predic …
Endovascular Thrombectomy.
Wu Y, Yin C, Yang J, Jiang L, Parsons MW, Lin L. Wu Y, et al. Stroke. 2018 Nov;49(11):2783-2785. doi: 10.1161/STROKEAHA.118.022919. Stroke. 2018. PMID: 30355186
Background and Purpose- This study aimed to explore safety of tirofiban in endovascular treatment of acute ischemic stroke. Methods- Two hundred eighteen ischemic stroke patients receiving endovascular thrombectomy were prospectively recruited, with 94 treated with intra-a …
Background and Purpose- This study aimed to explore safety of tirofiban in endovascular treatment of acute ischemic stroke. Methods- …
Tirofiban in emergency conditions.
Szarpak L, Rafique Z, Gasecka A, Jaguszewski MJ, Filipiak KJ. Szarpak L, et al. Am J Emerg Med. 2022 Jan;51:422-423. doi: 10.1016/j.ajem.2021.03.063. Epub 2021 Mar 24. Am J Emerg Med. 2022. PMID: 33824023 Review. No abstract available.
[GPIIb-IIIa inhibitors].
Nurden P. Nurden P. Transfus Clin Biol. 2001 Apr;8(2):114-22. doi: 10.1016/s1246-7820(01)00100-8. Transfus Clin Biol. 2001. PMID: 11386043 Review. French.
Two classes of products have been used in clinic, the chimeric monoclonal antibody Fab fragment, c7E3 or abciximab (ReoPro), which has been the pioneer, and synthetic peptides or peptidomimetics such as eptifibatide (Integrilin) or tirofiban (Agrastat). Abciximab is …
Two classes of products have been used in clinic, the chimeric monoclonal antibody Fab fragment, c7E3 or abciximab (ReoPro), which has been …
Tirofiban-Induced Severe Thrombocytopenia.
Liu YY, Dong QT, Guo YL, Wu NQ, Li JJ. Liu YY, et al. Am J Ther. 2019 Sep/Oct;26(5):e659-e661. doi: 10.1097/MJT.0000000000000861. Am J Ther. 2019. PMID: 31356349 No abstract available.
Anti-Platelet Peptides Targeting αIIbβ3 Outside-In Signaling Pathway.
Wang J, Xu X. Wang J, et al. Curr Protein Pept Sci. 2023;24(1):31-42. doi: 10.2174/1389203724666221114113413. Curr Protein Pept Sci. 2023. PMID: 36380406 Review.
Because of their quick and high efficacy, the three anti-alphaIIbbeta3 drugs, abciximab, eptifibatide, and tirofiban, are regarded as potent anti-thrombotics and clinically approved by US Food and Drug Administration. However, because they interfere with the inside-out sig …
Because of their quick and high efficacy, the three anti-alphaIIbbeta3 drugs, abciximab, eptifibatide, and tirofiban, are regarded as …
1,795 results